Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 138


Rationale and design of the glycemia reduction approaches in diabetes: a comparative effectiveness study (GRADE).

Nathan DM, Buse JB, Kahn SE, Krause-Steinrauf H, Larkin ME, Staten M, Wexler D, Lachin JM; GRADE Study Research Group.

Diabetes Care. 2013 Aug;36(8):2254-61. doi: 10.2337/dc13-0356. Epub 2013 May 20.


Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis.

Karagiannis T, Paschos P, Paletas K, Matthews DR, Tsapas A.

BMJ. 2012 Mar 12;344:e1369. doi: 10.1136/bmj.e1369.


Cost-effectiveness of sitagliptin-based treatment regimens in European patients with type 2 diabetes and haemoglobin A1c above target on metformin monotherapy.

Schwarz B, Gouveia M, Chen J, Nocea G, Jameson K, Cook J, Krishnarajah G, Alemao E, Yin D, Sintonen H.

Diabetes Obes Metab. 2008 Jun;10 Suppl 1:43-55. doi: 10.1111/j.1463-1326.2008.00886.x.


Safety, effectiveness, and cost of dipeptidyl peptidase-4 inhibitors versus intermediate acting insulin for type 2 diabetes: protocol for a systematic review and network meta-analysis.

Tricco AC, Antony J, Soobiah C, Hemmelgarn B, Moher D, Hutton B, Yu CH, Majumdar SR, Straus SE.

Syst Rev. 2013 Jun 28;2:47. doi: 10.1186/2046-4053-2-47.


Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.

Waugh N, Cummins E, Royle P, Clar C, Marien M, Richter B, Philip S.

Health Technol Assess. 2010 Jul;14(36):1-248. doi: 10.3310/hta14360. Review.


Efficacy and safety over 26 weeks of an oral treatment strategy including sitagliptin compared with an injectable treatment strategy with liraglutide in patients with type 2 diabetes mellitus inadequately controlled on metformin: a randomised clinical trial.

Charbonnel B, Steinberg H, Eymard E, Xu L, Thakkar P, Prabhu V, Davies MJ, Engel SS.

Diabetologia. 2013 Jul;56(7):1503-11. doi: 10.1007/s00125-013-2905-1. Epub 2013 Apr 19.


Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.

Deacon CF, Mannucci E, Ahrén B.

Diabetes Obes Metab. 2012 Aug;14(8):762-7. doi: 10.1111/j.1463-1326.2012.01603.x. Epub 2012 Apr 24. Review.


Cost-effectiveness of metformin plus vildagliptin compared with metformin plus sulphonylurea for the treatment of patients with type 2 diabetes mellitus: a Portuguese healthcare system perspective.

Viriato D, Calado F, Gruenberger JB, Ong SH, Carvalho D, Silva-Nunes J, Johal S, Viana R.

J Med Econ. 2014 Jul;17(7):499-507. doi: 10.3111/13696998.2014.912986. Epub 2014 Apr 23.


Cost-utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add-on to metformin monotherapy in Type 2 diabetes mellitus.

Davies MJ, Chubb BD, Smith IC, Valentine WJ.

Diabet Med. 2012 Mar;29(3):313-20. doi: 10.1111/j.1464-5491.2011.03429.x.


Contribution of liraglutide in the fixed-ratio combination of insulin degludec and liraglutide (IDegLira).

Buse JB, Vilsbøll T, Thurman J, Blevins TC, Langbakke IH, Bøttcher SG, Rodbard HW; NN9068-3912 (DUAL-II) Trial Investigators.

Diabetes Care. 2014 Nov;37(11):2926-33. doi: 10.2337/dc14-0785. Epub 2014 Aug 11.


Long-term clinical and economic outcomes associated with liraglutide versus sitagliptin therapy when added to metformin in the treatment of type 2 diabetes: a CORE Diabetes Model analysis.

Lee WC, Samyshkin Y, Langer J, Palmer JL.

J Med Econ. 2012;15 Suppl 2:28-37. doi: 10.3111/13696998.2012.716111. Epub 2012 Aug 13.


Sitagliptin as add-on therapy in insulin deficiency: biomarkers of therapeutic efficacy respond differently in type 1 and type 2 diabetes.

Giampietro O, Giampietro C, Bartola LD, Masoni MC, Matteucci E.

Drug Des Devel Ther. 2013;7:99-104. doi: 10.2147/DDDT.S38346. Epub 2013 Feb 14.


Health and economic outcomes for exenatide once weekly, insulin, and pioglitazone therapies in the treatment of type 2 diabetes: a simulation analysis.

Gaebler JA, Soto-Campos G, Alperin P, Cohen M, Blickensderfer A, Wintle M, Maggs D, Hoogwerf B, Han J, Pencek R, Peskin B.

Vasc Health Risk Manag. 2012;8:255-64. doi: 10.2147/VHRM.S28744. Epub 2012 Apr 23.


AHRQ's comparative effectiveness research on oral medications for type 2 diabetes: a summary of the key findings.

Bennett WL, Balfe LM, Faysal JM.

J Manag Care Pharm. 2012 Jan-Feb;18(1 Suppl A):1-22. Review.


Sequential intensification of metformin treatment in type 2 diabetes with liraglutide followed by randomized addition of basal insulin prompted by A1C targets.

DeVries JH, Bain SC, Rodbard HW, Seufert J, D'Alessio D, Thomsen AB, Zychma M, Rosenstock J; Liraglutide-Detemir Study Group.

Diabetes Care. 2012 Jul;35(7):1446-54. doi: 10.2337/dc11-1928. Epub 2012 May 14.


The evaluation of clinical and cost outcomes associated with earlier initiation of insulin in patients with type 2 diabetes mellitus.

Smolen HJ, Murphy DR, Gahn JC, Yu X, Curtis BH.

J Manag Care Spec Pharm. 2014 Sep;20(9):968-84.


Liraglutide achieves A1C targets more often than sitagliptin or exenatide when added to metformin in patients with type 2 diabetes and a baseline A1C <8.0%.

King AB, Montanya E, Pratley RE, Blonde L, Svendsen CB, Donsmark M, Sesti G.

Endocr Pract. 2013 Jan-Feb;19(1):64-72. doi: 10.4158/EP12232.OR.


Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients.

Rosenstock J, Sugimoto D, Strange P, Stewart JA, Soltes-Rak E, Dailey G.

Diabetes Care. 2006 Mar;29(3):554-9.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk